CureGene Unveils Groundbreaking Preclinical Data for CG-0416, a Novel Oral Non-GLP-1 Therapy, at Obesity Week 2025
CG-0416, a highly liver-targeted THR-B agonist, demonstrates high-quality weight loss by reducing fat mass while preserving muscle, both as a monotherapy and in combination with GLP-1 RAs. CureGene Pharmaceuticals (“CureGene”) today announced the first disclosure of groundbreaking preclinical data for CG-0416, a novel oral non-GLP-1 weight-loss agent, in the Late-Breaking poster session (Poster-350) at Obesity […]